Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

24.30 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 24.30
Bid (Size) 24.30 (2)
Ask (Size) 38.63 (1)
Prev. Close 24.30
Today's Range 24.30 - 24.30
52wk Range 13.37 - 32.27
Shares Outstanding 60,648,883
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Oncology Institute Announces Changes to Board of Directors
Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New Chairman 
From Toi Management, LLC
Via GlobeNewswire
Dianthus Therapeutics Inc (NASDAQ:DNTH) Q2 2025 Earnings: Revenue Misses, EPS Meets Estimates
Dianthus Therapeutics Q2 2025 earnings show revenue miss but EPS in line. Cash reserves strong, key clinical trials progressing with major data readouts expected in 2025-2026. 
Via Chartmill

Performance

YTD
+4.7%
+4.7%
1 Month
+13.0%
+13.0%
3 Month
+35.5%
+35.5%
6 Month
+12.5%
+12.5%
1 Year
-18.4%
-18.4%

More News

Read More
Dianthus (DNTH) Q2 Loss Widens 80%
Via The Motley Fool
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics
Via Benzinga
Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views
Via Benzinga
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts
Via Benzinga
Expert Ratings For Dianthus Therapeutics
Via Benzinga
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Friday's pre-market session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Dianthus Therapeutics, Inc. - Common Stock publicly traded?
Yes, Dianthus Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Dianthus Therapeutics, Inc. - Common Stock trade on?
Dianthus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Dianthus Therapeutics, Inc. - Common Stock?
The ticker symbol for Dianthus Therapeutics, Inc. - Common Stock is DNTH on the Nasdaq Stock Market
What is the current price of Dianthus Therapeutics, Inc. - Common Stock?
The current price of Dianthus Therapeutics, Inc. - Common Stock is 24.30
When was Dianthus Therapeutics, Inc. - Common Stock last traded?
The last trade of Dianthus Therapeutics, Inc. - Common Stock was at 08/22/25 04:00 PM ET
What is the market capitalization of Dianthus Therapeutics, Inc. - Common Stock?
The market capitalization of Dianthus Therapeutics, Inc. - Common Stock is 1.47B
How many shares of Dianthus Therapeutics, Inc. - Common Stock are outstanding?
Dianthus Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.